- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06285357
The Effect of the Association EGCG, Folic Acid and Vitamin B12 in Preventing the Persistence of HPV Infection.
March 15, 2024 updated by: Lo.Li.Pharma s.r.l
A Pilot Study to Test the Effect of the Association of Epigallocatechin Gallate (EGCG), Folic Acid and Vitamin B12 in Preventing the Persistence of Human Papilloma Virus (HPV) Infection.
The purpose of the study is to test the effect of the administration of a dietary supplement consisting of epigallocatechin gallate (EGCG), vitamin B12 and folic acid in the treatment of infections with papilloma virus of the cervix.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Giovanni Grandi
- Phone Number: +390594222830
- Email: giovanni.grandi@unimore.it
Study Locations
-
-
-
Modena, Italy, 41124
- Recruiting
- Azienda Ospedaliero-Universitaria di Modena
-
Contact:
- Giovanni Grandi
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- HR-HPV DNA test positivity
Exclusion Criteria:
- No HSIL
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: treatment
|
EGCG + folic acid + B12
|
No Intervention: control
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HPV DNA test negativity
Time Frame: 8 months of treatment
|
Percentage
|
8 months of treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 19, 2024
Primary Completion (Estimated)
February 1, 2025
Study Completion (Estimated)
December 1, 2025
Study Registration Dates
First Submitted
February 22, 2024
First Submitted That Met QC Criteria
February 28, 2024
First Posted (Actual)
February 29, 2024
Study Record Updates
Last Update Posted (Actual)
March 18, 2024
Last Update Submitted That Met QC Criteria
March 15, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Virus Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Disease Attributes
- DNA Virus Infections
- Tumor Virus Infections
- Urogenital Diseases
- Genital Diseases
- Infections
- Communicable Diseases
- Papillomavirus Infections
- Physiological Effects of Drugs
- Micronutrients
- Vitamins
- Vitamin B Complex
- Hematinics
- Folic Acid
Other Study ID Numbers
- EPISTOP_22
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HPV Infection
-
Lee's Pharmaceutical LimitedUnknownCervical HPV-16 and / or HPV-18 InfectionChina
-
Sinocelltech Ltd.RecruitingHPV Infection Vaccine Safety SCT1000China
-
Ulla Bonde van ZwolUniversity of Southern Denmark; Region of Southern Denmark; MCM Vaccines B.V.Unknown
-
PDS Biotechnology Corp.CompletedHigh-risk HPV Infection and Biopsy-proven CIN1United States
-
Capital Medical UniversityUnknown
-
Kenya Medical Research InstituteMerck Sharp & Dohme LLC; University of WashingtonCompletedHPV Infection | HPV Vaccine | HIV-1-infectionKenya
-
Merck Sharp & Dohme LLCCompletedHPV Infections
-
University of Alabama at BirminghamCompleted
-
Merck Sharp & Dohme LLCSuspended
-
University of WashingtonActive, not recruiting
Clinical Trials on EGCG + folic acid + B12
-
Universität des SaarlandesCompletedthe Effect of MTHFR C677T on Folate MetabolismGermany
-
Moshe FlugelmanTerminatedB12 Deficiency Combined With C677T Mutation on MTHFR GeneIsrael
-
Wageningen UniversityZonMw: The Netherlands Organisation for Health Research and DevelopmentCompletedCognitive Decline | Cognitive SymptomsNetherlands
-
Hamilton Health Sciences CorporationCanadian Institutes of Health Research (CIHR); Population Health Research InstituteUnknownCardiovascular Disease | AtherosclerosisCanada
-
AGUNCO Obstetrics and Gynecology CentreCompleted
-
Centro di Ricerca Clinica SalentinoActive, not recruitingPapilloma-induced Cervical LesionsItaly
-
Northwell HealthTerminatedParkinson's DiseaseUnited States
-
Tor A. StrandThrasher Research Fund; Society for Essential Health Action and Training, New...Completed
-
University of CataniaUnknownProliferative Diabetic Retinopathy | Non Proliferative Diabetic RetinopathyItaly
-
Haukeland University HospitalThe Research Council of Norway; The Royal Norwegian Ministry of Health; Norwegian... and other collaboratorsCompletedMyocardial Infarction | Coronary Artery Disease | Cerebrovascular StrokeNorway